Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

(2021) Jiali Yu et al.   NATURE MEDICINE

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

(2021) D.J. McGrail et al.   ANNALS OF ONCOLOGY

Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases

(2021) Chongkai Wang et al.   JAMA Network Open

Identification of an Immune-Related Signature Predicting Survival Risk and Immune Microenvironment in Gastric Cancer

(2021) Shuang Dai et al.   Frontiers in Cell and Developmental Biology

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

(2020) Sarina A. Piha-Paul et al.   INTERNATIONAL JOURNAL OF CANCER

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

(2020) Richard D. Kim et al.   JAMA Oncology

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

(2020) Rilan Bai et al.   Biomarker Research

Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).

(2019) Tatsuya Ioka et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.

(2019) Yung-Jue Bang et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital

(2018) Ria Winkelmann et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma

(2018) Richard Kim et al.   Oncotarget

625PDPembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study

(2018) M Ueno et al.   ANNALS OF ONCOLOGY

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

(2018) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

TMEM106a is a Novel Tumor Suppressor in Human Renal Cancer

(2017) Chenglong Wu et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

ZDHHC7-mediated S-palmitoylation of Scribble regulates cell polarity

(2016) Baoen Chen et al.   Nature Chemical Biology

Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer

(2013) B Goeppert et al.   BRITISH JOURNAL OF CANCER